Semnur Pharmaceuticals, Inc.

SMNR OTC CIK: 0001913577

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 960 SAN ANTONIO ROAD, PALO ALTO, CA, 94303
Mailing Address 960 SAN ANTONIO ROAD, PALO ALTO, CA, 94303
Phone (650) 516-4310
Fiscal Year End 1231
EIN 981659463

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 17, 2026 View on SEC
10-K Annual financial report February 27, 2026 View on SEC
S-1/A IPO registration amendment December 19, 2025 View on SEC
8-K Current report of material events December 3, 2025 View on SEC
10-Q Quarterly financial report November 12, 2025 View on SEC
S-1 IPO registration statement October 21, 2025 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment October 14, 2025 View on SEC
8-K Current report of material events September 26, 2025 View on SEC
3 Initial insider ownership report September 26, 2025 View on SEC
4 Insider stock transaction report September 25, 2025 View on SEC

Annual Reports

10-K February 27, 2026
  • Clinical-stage biopharmaceutical company developing product candidates for pain management.
  • Primary asset is SP-102, an investigational epidural steroid injection designed to treat sciatica.
View Analysis

Material Events

8-K Leadership Change March 17, 2026
High Impact
  • New leadership (Dr. Henry Ji as CEO, Stephen Ma as COO) brings extensive experience and strong ties to controlling shareholder Scilex Holding Company.
  • The transition signals a strategic shift towards tighter integration with Scilex, potentially leading to shared resources, streamlined decision-making, and faster development.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.